Creatine for neuroprotection in neurodegenerative disease: end of story?
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Creatine (Cr) is a natural compound that plays an important role in cellular energy homeostasis. In addition, it ameliorates oxidative stress, glutamatergic excitotoxicity, and apoptosis in vitro as well as in vivo. Since these pathomechanisms are implicated to play a role in several neurodegenerative diseases, Cr supplementation as a neuroprotective strategy has received a lot of attention with several positive animal studies in models of Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). This has led to a number of randomized clinical trials (RCT) with oral Cr supplementation, with durations up to 5 years. In this paper, we review the evidence and consequences stemming from these trials. In the case of PD, the initial phase II RCT was promising and led to a large and well-designed phase III trial, which, however, turned out to be negative for all outcome measures. None of the RCTs that have examined effects of Cr in ALS patients showed any clinical benefit. In HD, Cr in high doses (up to 30 g/day) was shown to slow down brain atrophy in premanifest Huntingtin mutation carriers. In spite of this, proof is still lacking that Cr can also have beneficial clinical effects in this group of patients, who will go on to develop HD symptoms. Taken together, the use of Cr supplementation has so far proved disappointing in clinical studies with a number of symptomatic neurodegenerative diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there was some evidence that creatine supplementation slowed down progression of brain atrophy in patients with HD (although clinical markers were unaffected).”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“clinical populations may need to consume 10–30 g/day throughout their lifespan to offset creatine synthesis deficiencies and/or provide therapeutic benefit in various disease states”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“However, higher levels of creatine supplementation for longer periods of time may be needed to increase brain concentrations of creatine, offset creatine synthesis deficiencies, or influence disease states”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“Results revealed no clinical benefit on patient outcomes in patients with PD or ALS.”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“Nevertheless, these studies show that creatine supplementation has been used to treat children and adults with neurodegenerative conditions and is apparently safe and well-tolerated when taking up to 30 g/day for 5 years in these populations.”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · cited 1×
“These mice show early mitochondrial swelling and vacuolization as well as altered electron transport chain enzyme activities, corresponding to similar mitochondrial abnormalities observed in post-mortem spinal cords of ALS patients (Gurney et al. 1994; Wong et al. 1995; Hervias et al. 2006).”
BackgroundStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 1×
“This prophylactic Cr loading seems unfeasible in the case of human neurodegenerative disease, where at symptom onset and time of diagnosis the neuropathological processes are believed to have been active for a long time (Braak et al. 2004).”
BackgroundWong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., & Price, D. L. (1995) · Neuron · doi:10.1016/0896-6273(95)90259-7 · Cited by 1,445 · cited 1×
“These mice show early mitochondrial swelling and vacuolization as well as altered electron transport chain enzyme activities, corresponding to similar mitochondrial abnormalities observed in post-mortem spinal cords of ALS patients (Gurney et al. 1994; Wong et al. 1995; Hervias et al. 2006).”
BackgroundFrom charcot to lou gehrig: deciphering selective motor neuron death in als
Cleveland, D. W., & Rothstein, J. D. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097565 · Cited by 1,389 · cited 18×
“For the case of Cr in ALS, data are also not encouraging.”
BackgroundInfluentialBeal, M., Brouillet, E., Jenkins, B., Ferrante, R., Kowall, N., Miller, J., Storey, E., Srivastava, R., Rosen, B., & Hyman, B. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,027 · cited 1×
“Systemic administration of the respiratory chain complex II inhibitors 3-nitropropionic acid or malonate to rats leads to a behavioural and neuropathological phenotype resembling human HD (Beal et al. 1993).”
BackgroundMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883 · cited 1×
“Even though its pathogenesis is far from understood, mitochondrial dysfunction and oxidative damage have been suggested to play a key role in PD (Schapira 2008).”
BackgroundThe creatine kinase system and pleiotropic effects of creatine
Wallimann, T., Tokarska-Schlattner, M., & Schlattner, U. (2011) · Amino Acids · doi:10.1007/s00726-011-0877-3 · Cited by 797 · cited 1×
“In combination with phosphocreatine (PCr) and the creatine kinases (CK), it serves as an efficient energy buffering and energy transportation system (Hemmer and Wallimann 1993; Wallimann et al. 2011).”
BackgroundNeuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682 · cited 1×
“Two Cr supplementation studies by the same group reported a dose-dependent increase in survival compared to placebo, reduction of neuronal cell death, as well as a delay of the motor phenotype, with 1–2 % of Cr, started within 1–2 months of animal age (Klivenyi et al. 1999; Andreassen et al. 2001b).”
BackgroundNeuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522 · cited 2×
“…with 30 g of Cr/day may also be reflected by the fact that in the typical mouse studies, brain Cr increased by 21 ± 3.8 % while in the human randomized trials, only increases between 7.5 and 13 % could be obtained (Ferrante et al. 2000; Atassi et al. 2010; Hersch et al. 2006; Lyoo et al. 2003).”
BackgroundInfluentialDesign, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504 · cited 3×
“They controlled for common methodological issues and confounders in animal studies, such as small animal numbers per group, lack of control for low transgene copy number, and deaths unrelated to ALS (Scott et al. 2008).”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · cited 4×
“In the same year, a so called futility RCT with 10 g of Cr per day in 200 early PD patients (n = 67 patients received Cr) for 12 months was published and showed that Cr could not be rejected as futile with regard to slowing clinical disease progression (NINDS NET-PD Investigators 2006).”
BackgroundMethodInfluentialDirect antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448 · cited 1×
“It also has anti-apoptotic, anti-excitotoxic, and direct anti-oxidative properties, both in vitro and in vivo (Bender et al. 2005; Genius et al. 2012; Lawler et al. 2002; O’Gorman et al. 1997).”
BackgroundThe pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease
Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R., & Beal, M. F. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 430 · cited 2×
“Neuroprotective Cr effects were demonstrated in rodent models, where Cr administration was begun weeks prior to initiation of the neurotoxin (Matthews et al. 1998, 1998; Yang et al. 2009).”
BackgroundCreatine and Cyclocreatine Attenuate MPTP Neurotoxicity
Matthews, R. T., Ferrante, R. J., Klivenyi, P., Yang, L., Klein, A. M., Mueller, G., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 373 · cited 2×
“The continuous evaluation of Cr as a neuroprotective agent in PD started in 1999 when it was shown to be strongly protective in a toxic mouse model for PD, targeting mitochondrial function (Matthews et al. 1999).”
BackgroundFunctions and effects of creatine in the central nervous system
Andres, R. H., Ducray, A. D., Schlattner, U., Wallimann, T., & Widmer, H. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.02.035 · Cited by 368 · cited 1×
“Cr is ergogenic and can stabilize cellular and neuronal energy homoeostasis, serving as an energy buffer in times of energy crisis (Balestrino et al. 2002; Andres et al. 2008).”
BackgroundMitochondrial loss, dysfunction and altered dynamics in Huntington's disease
Kim, J., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Cormier, K., Smith, K., Beal, M. F., & Ferrante, R. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq306 · Cited by 357 · cited 1×
“The mechanisms by which mutant huntingtin is believed to exert its neurotoxic effects suggest a mitochondrial dysfunction with perturbation of energy homoeostasis, oxidative stress, and excitotoxicity (Lodi et al. 2000; Tabrizi et al. 1999; Kim et al. 2010).”
BackgroundEmerging mechanisms of molecular pathology in ALS
Peters, O. M., Ghasemi, M., & Brown, R. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci71601 · Cited by 313 · cited 1×
“About 10 % of the cases are caused by pathogenic gene mutations, one of the most common ones being in copper/zinc superoxide dismutase (SOD1), a cytosolic enzyme responsible for scavenging oxidative stress in the cell (Peters et al. 2015).”
BackgroundCreatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · cited 3×
“…with 30 g of Cr/day may also be reflected by the fact that in the typical mouse studies, brain Cr increased by 21 ± 3.8 % while in the human randomized trials, only increases between 7.5 and 13 % could be obtained (Ferrante et al. 2000; Atassi et al. 2010; Hersch et al. 2006; Lyoo et al. 2003).”
BackgroundInfluentialAndreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293 · cited 2×
“There, Cr also provided significant neuroprotection, improvement in motor performance, and higher overall survival in two different transgenic mouse models, when oral supplementation started prior to the development of the phenotype (Ferrante et al. 2000; Andreassen et al. 2001a).”
BackgroundA clinical trial of creatine in ALS
Shefner, J. M., Cudkowicz, M. E., Schoenfeld, D., Conrad, T., Taft, J., Chilton, M., Urbinelli, L., Qureshi, M., Zhang, H., Pestronk, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142992.81995.f0 · Cited by 293
A randomized sequential trial of creatine in amyotrophic lateral sclerosis
Jan Groeneveld, G., Veldink, J. H., van der Tweel, I., Kalmijn, S., Beijer, C., de Visser, M., Wokke, J. H. J., Franssen, H., & Berg, L. H. V. D. (2003) · Annals of Neurology · doi:10.1002/ana.10554 · Cited by 283 · cited 2×
“…b Creatine monohydrate was used in all studies Event-free survival (n.s.), muscle strength (n.s.), vital capacity (n.s.), ALSFRS (n.s.), QOL (n.s.) Groeneveld et al. (2003) Muscle strength (n.s.), safety (n.s.), ALSFRS (n.s.), vital capacity (n.s.), QOL (n.s.), survival (n.s.) Rosenfeld et al.…”
BackgroundMethodLodi, R., Schapira, A. H. V., Manners, D., Styles, P., Wood, N. W., Taylor, D. J., & Warner, T. T. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1<72::aid-ana11>3.0.co;2-i · Cited by 254 · cited 1×
“The mechanisms by which mutant huntingtin is believed to exert its neurotoxic effects suggest a mitochondrial dysfunction with perturbation of energy homoeostasis, oxidative stress, and excitotoxicity (Lodi et al. 2000; Tabrizi et al. 1999; Kim et al. 2010).”
BackgroundParkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype
Klein, C., Pramstaller, P. P., Kis, B., Page, C. E., Kann, M., Leung, J., Woodward, H., Castellan, C. C., Scherer, M., Vieregge, P., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1<65::aid-ana10>3.0.co;2-l · Cited by 243
Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study
Braissant, O., Henry, H., Loup, M., Eilers, B., & Bachmann, C. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00269-2 · Cited by 232 · cited 1×
“This transporter is necessary for the uptake of Cr into neuronal cells (Braissant et al. 2001).”
BackgroundYang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Flint Beal, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 231 · cited 3×
“Neuroprotective Cr effects were demonstrated in rodent models, where Cr administration was begun weeks prior to initiation of the neurotoxin (Matthews et al. 1998, 1998; Yang et al. 2009).”
BackgroundThe pathogenesis of cell death in Parkinson's disease – 2007
Olanow, C. W. (2007) · Movement Disorders · doi:10.1002/mds.21675 · Cited by 211
The role of creatine kinase in inhibition of mitochondrial permeability transition
(1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01045-4 · Cited by 210 · cited 1×
“It also has anti-apoptotic, anti-excitotoxic, and direct anti-oxidative properties, both in vitro and in vivo (Bender et al. 2005; Genius et al. 2012; Lawler et al. 2002; O’Gorman et al. 1997).”
BackgroundKieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
Bender, A., Koch, W., Elstner, M., Schombacher, Y., Bender, J., Moeschl, M., Gekeler, F., Müller-Myhsok, B., Gasser, T., Tatsch, K., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000238518.34389.12 · Cited by 204 · cited 2×
“Encouraged by the impressive neuroprotective capacity of Cr in animal models, we conducted a randomized placebo-controlled clinical trial (RCT) of oral Cr supplementation (up to 4 g per day) over 2 years in 60 PD patients (Bender et al. 2006).”
BackgroundMethodSelf-citationKlivenyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., & Beal, M. F. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02160.x · Cited by 200 · cited 2×
“In contrast, the combination of minocycline (a tetracycline antibiotic with neuroprotective properties) and Cr as well as the combination of Cr with the COX-2 inhibitors celecoxib and/or rofecoxib produced additive neuroprotective effects (Zhang et al. 2003; Klivenyi et al. 2004).”
BackgroundNeuroprotective effects of creatine
Beal, M. F. (2011) · Amino Acids · doi:10.1007/s00726-011-0851-0 · Cited by 188 · cited 1×
“Several reviews have already highlighted the neuroprotective effect of Cr in neurodegenerative disease and have expressed high hopes for its evaluation in clinical phase II and III studies (Beal 2011; Klopstock et al. 2011; Smith et al. 2014).”
BackgroundAdditive neuroprotective effects of minocycline with creatine in a mouse model of ALS
Zhang, W., Narayanan, M., & Friedlander, R. M. (2003) · Annals of Neurology · doi:10.1002/ana.10476 · Cited by 184 · cited 2×
“In contrast, the combination of minocycline (a tetracycline antibiotic with neuroprotective properties) and Cr as well as the combination of Cr with the COX-2 inhibitors celecoxib and/or rofecoxib produced additive neuroprotective effects (Zhang et al. 2003; Klivenyi et al. 2004).”
BackgroundAdverse Effects of Creatine Supplementation: Fact or Fiction?
Poortmans, J. R., & Francaux, M. (2000) · Sports Medicine · doi:10.2165/00007256-200030030-00002 · Cited by 176
In sickness and in health: the widespread application of creatine supplementation
Gualano, B., Roschel, H., Lancha, A. H., Brightbill, C. E., & Rawson, E. S. (2012) · Amino Acids · doi:10.1007/s00726-011-1132-7 · Cited by 172 · cited 2×
“In addition, it is being tested for several clinical indications outside the neurodegeneration field, such as in myopathies, psychiatric, or cardiac disease (Gualano et al. 2012).”
BackgroundDedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · cited 2×
“Even more relevant to application in human disease, the same effect was obtained when Cr was commenced after symptom onset (Dedeoglu et al. 2003).”
BackgroundFunctional Aspects of Creatine Kinase in Brain
Hemmer, W., & Wallimann, T. (1993) · Developmental Neuroscience · doi:10.1159/000111342 · Cited by 166 · cited 1×
“In combination with phosphocreatine (PCr) and the creatine kinases (CK), it serves as an efficient energy buffering and energy transportation system (Hemmer and Wallimann 1993; Wallimann et al. 2011).”
BackgroundCreatine supplementation in Huntington’s disease: A placebo-controlled pilot trial
Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S., Vanhees, L., Van Leemputte, M., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 161 · cited 1×
“In the first, 5 g of Cr for 1 year had no effect on clinical outcome measures in 41 HD patients (Verbessem et al. 2003).”
BackgroundTurner, C. E., Byblow, W. D., & Gant, N. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3113-14.2015 · Cited by 157 · cited 1×
“In fact, Cr was recently shown to prevent neuropsychological deficits in healthy volunteers under experimental oxygen deprivation (Turner et al. 2015).”
BackgroundCreatine supplementation lowers brain glutamate levels in Huntington?s disease
Bender, A., Auer, D. P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0595-4 · Cited by 144 · cited 4×
“Despite the possible dosing issues, Cr has the same biological effect for example on reduction of glutamatergic signals in human MR spectroscopy studies as in in vitro studies (Atassi et al. 2010; Bender et al. 2005; Genius et al. 2012).”
BackgroundInfluentialSelf-citationLyoo, I. K., Kong, S. W., Sung, S. M., Hirashima, F., Parow, A., Hennen, J., Cohen, B. M., & Renshaw, P. F. (2003) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(03)00046-5 · Cited by 140 · cited 3×
“…with 30 g of Cr/day may also be reflected by the fact that in the typical mouse studies, brain Cr increased by 21 ± 3.8 % while in the human randomized trials, only increases between 7.5 and 13 % could be obtained (Ferrante et al. 2000; Atassi et al. 2010; Hersch et al. 2006; Lyoo et al. 2003).”
BackgroundInfluentialCaffeine and creatine use in sport
Tarnopolsky, M. A. (2010) · Annals of Nutrition and Metabolism · doi:10.1159/000322696 · Cited by 130 · cited 2×
“Cr is in wide and relatively uncontrolled use by athletes (Tarnopolsky 2010).”
BackgroundAndreassen, O. A., Jenkins, B. G., Dedeoglu, A., Ferrante, K. L., Bogdanov, M. B., Kaddurah‐Daouk, R., & Beal, M. F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00188.x · Cited by 123 · cited 2×
“There, Cr also provided significant neuroprotection, improvement in motor performance, and higher overall survival in two different transgenic mouse models, when oral supplementation started prior to the development of the phenotype (Ferrante et al. 2000; Andreassen et al. 2001a).”
BackgroundMitochondrial dysfunction and amyotrophic lateral sclerosis
Hervias, I., Beal, M. F., & Manfredi, G. (2006) · Muscle & Nerve · doi:10.1002/mus.20489 · Cited by 122 · cited 1×
“These mice show early mitochondrial swelling and vacuolization as well as altered electron transport chain enzyme activities, corresponding to similar mitochondrial abnormalities observed in post-mortem spinal cords of ALS patients (Gurney et al. 1994; Wong et al. 1995; Hervias et al. 2006).”
BackgroundCreatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS
Rosenfeld, J., King, R. M., Jackson, C. E., Bedlack, R. S., Barohn, R. J., Dick, A., Phillips, L. H., Chapin, J., Gelinas, D. F., & Lou, J.-S. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802028890 · Cited by 107 · cited 2×
“The same was true for a study on 104 ALS patients with 5 g of Cr over a time period of 6 months and yet another multicentre trial with 5 g in 107 patients over 9 months (Shefner et al. 2004; Rosenfeld et al. 2008).”
BackgroundThe influence of creatine supplementation on the cognitive functioning of vegetarians and omnivores
Benton, D., & Donohoe, R. (2011) · British Journal of Nutrition · doi:10.1017/s0007114510004733 · Cited by 101 · cited 1×
“It was suggested that healthy vegetarian women had improved memory functions compared to omnivores upon supplementation of 20 g of Cr for 5 days (Benton and Donohoe 2011).”
BackgroundPRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D., Doros, G., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J.-P., Triggs, T. D., Wilkens, P. J., Matson, W., Salat, D. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000187 · Cited by 98 · cited 5×
“This is why the recent publication by Rosas and colleagues is so noteworthy, because they found a way to give Cr to premanifest HD patients, i.e. much earlier in the disease process than after establishment of the clinical diagnosis (Rosas et al. 2014).”
BackgroundMethodInfluentialRole of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage
Balestrino, M., Lensman, M. V., Parodi, M., Perasso, L., Rebaudo, R., Melani, R., Polenov, S. A., & Cupello, A. (2002) · Amino Acids · doi:10.1007/s00726-001-0133-3 · Cited by 91 · cited 1×
“Cr is ergogenic and can stabilize cellular and neuronal energy homoeostasis, serving as an energy buffer in times of energy crisis (Balestrino et al. 2002; Andres et al. 2008).”
BackgroundKlivènyi, P., Gardian, G., Calingasan, N. Y., Yang, L., & Beal, M. F. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:3:191 · Cited by 91 · cited 1×
“The same group replicated this result in 2003 and reported additive neuroprotective effects, when Cr was combined with the cyclooxygenase 2 (COX-2) inhibitor rofecoxib (Klivenyi et al. 2003).”
BackgroundA review of creatine supplementation in age-related diseases: more than a supplement for athletes
Smith, R. N., Agharkar, A. S., & Gonzales, E. B. (2014) · F1000Research · doi:10.12688/f1000research.5218.1 · Cited by 82 · cited 1×
“Several reviews have already highlighted the neuroprotective effect of Cr in neurodegenerative disease and have expressed high hopes for its evaluation in clinical phase II and III studies (Beal 2011; Klopstock et al. 2011; Smith et al. 2014).”
BackgroundThorsteinsdottir, B., Grande, J. P., & Garovic, V. D. (2006) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2006.04.025 · Cited by 80 · cited 1×
“Possible safety concerns regarding alleged deleterious effects of Cr on renal function have repeatedly been raised in the scientific field, as well as by the lay press (Thorsteinsdottir et al. 2006; Poortmans and Francaux 2000).”
BackgroundLong-term creatine supplementation is safe in aged patients with Parkinson disease
Bender, A., Samtleben, W., Elstner, M., & Klopstock, T. (2008) · Nutrition Research · doi:10.1016/j.nutres.2008.01.001 · Cited by 79 · cited 3×
“In the trials summarized in Tables 1–3, the only side effects that occurred with higher frequency in the Cr group than in the placebo group were nausea, diarrhoea, and overall gastrointestinal symptoms (Bender et al. 2008; Rosas et al. 2014).”
BackgroundSelf-citationKinetics of creatine in blood and brain after intraperitoneal injection in the rat
Perasso, L., Cupello, A., Lunardi, G. L., Principato, M. C., Gandolfo, C., & Balestrino, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02547-2 · Cited by 77 · cited 1×
“Cr does not readily cross the blood–brain barrier so that its neuronal uptake relies on the CrT, which seems to be differentially expressed in the brain with low transport efficiency in disease-critical brain areas, such as the basal ganglia in PD (Lowe et al. 2015; Perasso et al. 2003).”
BackgroundLi, Z., Wang, P., Yu, Z., Cong, Y., Sun, H., Zhang, J., Zhang, J., Sun, C., Zhang, Y., & Ju, X. (2015) · European Neurology · doi:10.1159/000377676 · Cited by 76 · cited 4×
“d) compared to placebo on motor as well as cognitive functioning in 75 PD patients with mild cognitive impairment (MCI) (Li et al. 2015).”
BackgroundInfluentialImmunohistochemical localisation of the creatine transporter in the rat brain
Mak, C., Waldvogel, H. J., Dodd, J. R., Gilbert, R. T., Lowe, M. T. J., Birch, N. P., Faull, R. L. M., & Christie, D. L. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.06.065 · Cited by 70 · cited 3×
“Considering the relatively low expression of the CrT in human and rat basal ganglia and substantia nigra, the possibly much higher Cr dose in the animal studies might partially account for the lack of translation to the human disease situation, because neurons with low CrT expression might just need higher Cr plasma c…”
BackgroundAllen, P. J., D'Anci, K. E., Kanarek, R. B., & Renshaw, P. F. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.005 · Cited by 60 · cited 1×
“For example, it would be of special interest, if women with PD were more likely to profit, given that rodent models of depression suggest a therapeutic Cr gender effect, favouring female animals (Allen et al. 2012).”
BackgroundCreatine for amyotrophic lateral sclerosis/motor neuron disease
Pastula, D. M., Moore, D. H., & Bedlack, R. S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005225.pub2 · Cited by 55 · cited 2×
“1 3 Not surprising, a systematic Cochrane collaboration meta-analysis covering these three individual RCTs with a total of 386 patients found no benefit of Cr in any of the chosen outcome domains (Pastula et al. 2012).”
BackgroundLowe, M. T. J., Faull, R. L. M., Christie, D. L., & Waldvogel, H. J. (2015) · Journal of Comparative Neurology · doi:10.1002/cne.23667 · Cited by 54 · cited 6×
“they should be susceptible to Cr neuroprotection (Lowe et al. 2015).”
BackgroundInfluentialSnow, R. J., Turnbull, J., da Silva, S., Jiang, F., & Tarnopolsky, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00212-4 · Cited by 54 · cited 1×
“Here, the neuroprotective Cr effect was comparable but not additive to the standard clinical ALS drug, riluzole (Snow et al. 2003).”
ResultCreatine in mouse models of neurodegeneration and aging
Klopstock, T., Elstner, M., & Bender, A. (2011) · Amino Acids · doi:10.1007/s00726-011-0850-1 · Cited by 53 · cited 1×
“Several reviews have already highlighted the neuroprotective effect of Cr in neurodegenerative disease and have expressed high hopes for its evaluation in clinical phase II and III studies (Beal 2011; Klopstock et al. 2011; Smith et al. 2014).”
BackgroundSelf-citationCreatine Protects against Excitoxicity in an In Vitro Model of Neurodegeneration
Genius, J., Geiger, J., Bender, A., Möller, H.-J., Klopstock, T., & Rujescu, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030554 · Cited by 51 · cited 2×
“Despite the possible dosing issues, Cr has the same biological effect for example on reduction of glutamatergic signals in human MR spectroscopy studies as in in vitro studies (Atassi et al. 2010; Bender et al. 2005; Genius et al. 2012).”
BackgroundSelf-citationYazigi Solis, M., de Salles Painelli, V., Giannini Artioli, G., Roschel, H., Concepción Otaduy, M., & Gualano, B. (2014) · British Journal of Nutrition · doi:10.1017/s0007114513003802 · Cited by 46 · cited 1×
“On the other hand, a recent proton MRS study showed that brain Cr content was not related to dietary Cr intake (Yazigi Solis et al. 2014).”
BackgroundSolving the lost in translation problem: Improving the effectiveness of translational research
Ergorul, C., & Levin, L. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.005 · Cited by 44 · cited 1×
“It remains unclear why there seems to be a species barrier between man and mice with regard to Cr-mediated neuroprotection in neurodegenerative disease, but this phenomenon does not appear to be specific to failed Cr trials [for review: (Ergorul and Levin 2013)].”
BackgroundTherapeutic use of creatine in brain or heart ischemia: Available data and future perspectives
Perasso, L., Spallarossa, P., Gandolfo, C., Ruggeri, P., & Balestrino, M. (2013) · Medicinal Research Reviews · doi:10.1002/med.20255 · Cited by 43 · cited 3×
“It is therefore worth contemplating different routes of application , chemical forms, and analogues compounds, in order to overcome the issue of low neuronal uptake (reviewed in Perasso et al. 2013).”
BackgroundInfluentialAtassi, N., Ratai, E.-M., Greenblatt, D. J., Pulley, D., Zhao, Y., Bombardier, J., Wallace, S., Eckenrode, J., Cudkowicz, M., & Dibernardo, A. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482961003797130 · Cited by 37 · cited 4×
“…with 30 g of Cr/day may also be reflected by the fact that in the typical mouse studies, brain Cr increased by 21 ± 3.8 % while in the human randomized trials, only increases between 7.5 and 13 % could be obtained (Ferrante et al. 2000; Atassi et al. 2010; Hersch et al. 2006; Lyoo et al. 2003).”
BackgroundInfluentialCreatine for amyotrophic lateral sclerosis/motor neuron disease
Pastula, D. M., Moore, D. H., & Bedlack, R. S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005225.pub3 · Cited by 33
Testing a Novel Strategy Against Parkinson's Disease
Couzin, J. (2007) · Science · doi:10.1126/science.315.5820.1778 · Cited by 31
In vivo neuroprotection by a creatine-derived compound: Phosphocreatine–Mg-complex acetate
Perasso, L., Adriano, E., Ruggeri, P., Burov, S. V., Gandolfo, C., & Balestrino, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.009 · Cited by 31 · cited 1×
“Cr-derived compounds with increased blood– brain barrier penetrance and increased neuronal uptake, such as cyclocreatine or PCr-magnesium-complex-acetate have been shown to be neuroprotective in vitro and in animal studies (Matthews et al. 1999; Perasso et al. 2008, 2009).”
BackgroundProtective Effects of Some Creatine Derivatives in Brain Tissue Anoxia
Perasso, L., Lunardi, G. L., Risso, F., Pohvozcheva, A. V., Leko, M. V., Gandolfo, C., Florio, T., Cupello, A., Burov, S. V., & Balestrino, M. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9492-9 · Cited by 29 · cited 1×
“Cr-derived compounds with increased blood– brain barrier penetrance and increased neuronal uptake, such as cyclocreatine or PCr-magnesium-complex-acetate have been shown to be neuroprotective in vitro and in animal studies (Matthews et al. 1999; Perasso et al. 2008, 2009).”
BackgroundStevens, P., Gawryluk, J. W., Hui, L., Chen, X., & Geiger, J. D. (2015) · Current HIV Research · doi:10.2174/1570162x13666150121101544 · Cited by 22 · cited 1×
“Yet, a recent in vitro study showed, that there may be a rather complex U-shaped dose–response curve for a neuroprotective Cr effect (Stevens et al. 2014).”
BackgroundCreatine for Parkinson's disease
Xiao, Y., Luo, M., Luo, H., & Wang, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009646.pub2 · Cited by 18 · cited 1×
“A meta-analysis of the 194 patients of the two pilot or Phase II trials revealed no effect on either motor function or activities of daily living (ADL) but concluded that data was insufficient to draw a firm conclusion (Xiao et al. 2014).”
BackgroundAhlskog, J. E. (2007) · Neurology · doi:10.1212/01.wnl.0000277645.60799.0e · Cited by 14
Brew, B. J. (2007) · Neurology · doi:10.1212/01.wnl.0000277530.05450.ff · Cited by 9
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
Research works printed but not linked: 3
- National Academies of Sciences, Engineering, and Medicine (2015) Reproducibility issues in research with animals and animal models: workshop in Brief. The National Academies Press, Washington, DC, 1–8. ISBN 978-0-309-38017-1
- Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45(1):25–32 · doi:10.1002/1531-8249(199901)45:1<25::aid-art6>3.0.co;2-e
- Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem 109(5):1427–1439. doi: 10.1111/j.1471-4159.2009.06074.x · DOI · Paper page
Cited by
Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 1,057
“Moreover, long-term, high dose ingestion of creatine (up to 30 g/d for up to 5 years) in patient populations has not been associated with an increased incidence of renal dysfunction [23, 155, 156, 172].”
BackgroundInfluentialCreatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
“However, a large multi-site clinical trial conducted by Bender and coworkers [51] on PD, HD, and ALS patients did not find promising results.”
BackgroundMetabolic Basis of Creatine in Health and Disease: A Bioinformatics-Assisted Review
Bonilla, D. A., Kreider, R. B., Stout, J. R., Forero, D. A., Kerksick, C. M., Roberts, M. D., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13041238 · Cited by 223
“Brain BB-CK uMtCK Supports brain cells energy production and buffers ATP and ion pumping during electrical activity in neurons [50].”
BackgroundDolan, E., Gualano, B., & Rawson, E. S. (2019) · European Journal of Sport Science · doi:10.1080/17461391.2018.1500644 · Cited by 171
“…2017; Devries & Phillips, 2014; Gualano, Rawson, Candow, & Chilibeck, 2016; Rawson & Venezia, 2011), and patient populations (reviewed in Bender & Klopstock, 2016; Gualano, Roschel, Lancha, Brightbill, & Rawson, 2012) have also been thoroughly researched and © 2018 European College of Sport…”
Effects of creatine supplementation on brain function and health
Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojic, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 145
Metadata
- Authors
- Bender, A., & Klopstock, T.
- Affiliations
- Therapiezentrum Burgau (DE)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Bender, Andreas
- Venue
- Amino Acids
- Published
- 2016-01-09
- Volume
- 48
- Issue
- 8
- Pages
- 1929-1940
- ISSN
- 0939-4451 (ISSN-L)
- 1438-2199
- OpenAlex
- W2231841779
- Cited by
- 96
- References
- 73
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 12 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 7
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Amino Acids (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Physiology (medical) › Biochemical effects in animals
- Keywords
- creatine supplementation, neuroprotection, neurodegenerative diseases, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, oxidative stress, glutamate excitotoxicity, apoptosis, brain atrophy, clinical trial results, energy homeostasis
- MeSH terms
- Animals, Creatine, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Randomized Controlled Trials as Topic, Neuroprotective Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.